To add to the controversy, 3 large cohort studies that evaluated long-term outcomes in patients on AAB undergoing anesthesia arrived at remarkably conflicting conclusions. Railton et al11 found increased mortality in vascular surgery patients with the perioperative continuation of AAB. Toppin et al12reported decreased mortality with the continuation of these drugs in noncardiac surgical patients, whereas Turan et al13 found no difference in 30-day mortality in this population.
Additionally, there has been inconsistency regarding the association between perioperative AAB and the development of end-organ damage. The incidence of acute kidney injury (AKI) in patients on perioperative AAB undergoing vascular surgery,14 thoracic surgery,15 and orthopedic surgery16 has been shown to be increased. However, the incidence of AKI in the same population following cardiac surgery has been shown in certain studies to be increased,17-19unchanged,20 and even decreased.21,22
Likewise, there has been a discrepancy in the reported perioperative mortality of patients on AAB. In different studies, mortality has been shown to be increased,18,20,22 not different,13 or even decreased.23 Similarly, the development of atrial fibrillation in post–cardiopulmonary bypass (CPB) patients on perioperative AAB has been shown to be increased.20,24 However, the evidence for these associated complications, overall, is weak and based primarily on observational data.
http://www.anesthesiologynews.com/R...gs-In-the-Perioperative-Period/35357/ses=ogst
Medscape: Medscape Access (the evidence now strongly suggests to discontinue ARBS/ACE 24 hours prior to surgey)